Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial
Moustafa, A., Abd Elhady, S., Shalaby, H., Elrefaie, W. (2020). Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial. EKB Journal Management System, 10(3), 209-215. doi: 10.21608/ebwhj.2020.29798.1096
A. Moustafa; S. Abd Elhady; H. Shalaby; waleed Elrefaie. "Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial". EKB Journal Management System, 10, 3, 2020, 209-215. doi: 10.21608/ebwhj.2020.29798.1096
Moustafa, A., Abd Elhady, S., Shalaby, H., Elrefaie, W. (2020). 'Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial', EKB Journal Management System, 10(3), pp. 209-215. doi: 10.21608/ebwhj.2020.29798.1096
Moustafa, A., Abd Elhady, S., Shalaby, H., Elrefaie, W. Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial. EKB Journal Management System, 2020; 10(3): 209-215. doi: 10.21608/ebwhj.2020.29798.1096

Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial

Evidence Based Women's Health Journal
Article 4, Volume 10, Issue 3, September 2020, Page 209-215  XML PDF (1.17 MB)
Document Type: Original Article
DOI: 10.21608/ebwhj.2020.29798.1096
View on SCiNiTO View on SCiNiTO
Authors
A. Moustafa1; S. Abd Elhady2; H. Shalaby3; waleed Elrefaie email orcid 4
1Department of Obstetrics and Gynecology, Faculty of Medicine, Nabarou Central Hospital
2Department of Obstetrics and Gynecology, Faculty of Medicine, Mansoura University
3Mansoura University, Department of Obstetrics and Gynecology, Faculty of Medicine
4Departement of Obstetrics and Gynecology, Faculty of Medicine, Port Said University
Abstract
Aim: This study aimed to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section in low risk patients.
Materials and Methods: This randomized controlled study enrolled 300 patients who were eligible. 150 women received carbetocin100ug i.v intra-operative immediately after extraction of the fetus during cesarean section (group A). They were compared to 150 women who received misoprostol 600ug rectally immediately before sterilization during caesarean section (group B).
Results: There is significant difference in intraoperative uterine atony [3 (2.0%) vs 11 (7.3%) P < 0.02] and the need for blood transfusion [2 (1.2%) vs 10 (6.7%) P > 0.018] and surgical hemostatic measures as uterine artery ligation and uterine compression sutures [0.00 vs 3.00 (2%) P < 0.00 and 0.00 vs 12.00 (8%) P < 0.00] were higher in misopristol group. Also, the need for other uterotonic drugs was significantly higher in misopristol group (10.0 ± 0.0 vs 13.15 ± 5.28, P < 0.001 and the difference in hemoglobin and hematocrit values before and after delivery were slightly higher in misopristol group with no statistical significance (10.71 ± 0.98 vs 10.86 ± 0.84, P < 0.15 and 33.86 ± 2.8 vs 34.29 ± 2.7, P < 0.17).
Conclusion: Intravenous therapy infusion of 100 ug carbetocin reduced but no significantly blood loss during cesarean section than 600ug rectal misoprostol.
Keywords
Carbetocin; cesarean section; oxytocin; postpartum hemorrhage
Statistics
Article View: 290
PDF Download: 605